PFE · Pfizer Inc · Documents

Dec 17

Current report 8-K

Regulation FD disclosure

Nov 4

Quarterly report 10-Q FY2024 Q3, ended Sep 29

Quarterly report for FY2024 Q3

Revenue $17.7B ▲ 31.2% Net income $4.47B Diluted EPS $0.78

Oct 29

Current report 8-K

Financial results

Oct 15

Current report 8-K Events of Oct 10

Director or officer change, or executive pay

Sep 13

Tender offer SC TO-I/A

Tender offer

Aug 22

Tender offer SC TO-I/A

Tender offer

Aug 12

Tender offer SC TO-I

Tender offer

Aug 5

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Revenue $13.28B ▲ 2.1% Net income $41M ▼ 98.2% Diluted EPS $0.01 ▼ 97.6%

Aug 1

Tender offer SC TO-C

Tender offer

Jul 30

Earnings call

Q2 2024 earnings call

Jul 30

Current report 8-K

Financial results

Jul 30

Tender offer SC TO-C

Tender offer

Jul 26

Current report 8-K Events of Jul 24

Director or officer change, or executive pay, Other events

Jul 26

Tender offer SC TO-C

Tender offer

Jul 10

Current report 8-K Events of Jul 9

Director or officer change, or executive pay

Jul 1

Current report 8-K Events of Jun 27

Director or officer change, or executive pay

May 22

Current report 8-K

Exit or restructuring costs

May 8

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Revenue $14.88B ▼ 19.5% Net income $3.12B ▼ 43.8% Diluted EPS $0.55 ▼ 43.3%

May 1

Earnings call

Q1 2024 earnings call

May 1

Current report 8-K

Financial results

Apr 29

Current report 8-K Events of Apr 25

Shareholder vote results

Apr 11

Proxy statement DEFA14A

Proxy statement

Apr 11

Proxy statement DEFA14A

Proxy statement

Apr 11

Proxy statement DEFA14A

Proxy statement

Apr 9

Proxy statement DEFA14A

Proxy statement

Mar 28

Proxy statement DEFA14A

Proxy statement

Mar 28

Proxy statement DEFA14A

Proxy statement

Mar 14

Proxy statement DEF 14A Meeting Apr 25, 2024

Proxy statement

Mar 14

Annual report to holders ARS

Annual report to holders

Mar 14

Proxy statement DEFA14A

Proxy statement

Feb 23

Registration statement S-3ASR

Registration statement

Feb 22

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $58.5B ▼ 41.7% Net income $2.12B ▼ 93.2% Diluted EPS $0.37 ▼ 93.2%

Jan 30

Earnings call

Q4 2023 earnings call

Jan 30

Current report 8-K

Financial results

Jan 10

Current report 8-K

Other events

Dec 14

Current report 8-K/A

Completed an acquisition or sale of assets, Regulation FD disclosure

Dec 14

Current report 8-K

Financial results, Regulation FD disclosure

Dec 13

Current report 8-K

Regulation FD disclosure

Dec 12

Current report 8-K Events of Dec 7

Director or officer change, or executive pay, Regulation FD disclosure

Nov 8

Quarterly report 10-Q FY2023 Q3, ended Oct 1

Quarterly report for FY2023 Q3

Revenue $13.23B ▼ 41.5% Net loss $2.38B Diluted EPS -$0.42

Oct 31

Current report 8-K

Financial results

Oct 31

Earnings call

Q3 2023 earnings call

Oct 13

Current report 8-K

Financial results, Exit or restructuring costs, Regulation FD disclosure

Aug 9

Quarterly report 10-Q FY2023 Q2, ended Jul 2

Quarterly report for FY2023 Q2

Revenue $12.73B ▼ 54.1% Net income $2.33B ▼ 76.5% Diluted EPS $0.41 ▼ 76.3%

Aug 1

Current report 8-K

Financial results

Aug 1

Earnings call

Q2 2023 earnings call

Jul 27

Current report 8-K Events of Jul 21

Director or officer change, or executive pay

May 19

Current report 8-K Events of May 16

Other events

May 15

Current report 8-K Events of May 12

Other events

May 10

Quarterly report 10-Q FY2023 Q1, ended Apr 2

Quarterly report for FY2023 Q1

Revenue $18.28B ▼ 28.8% Net income $5.54B ▼ 29.5% Diluted EPS $0.97 ▼ 29.2%